menu
    • menu

    Company profile for XGen Pharmaceuticals

    Metrochem has been delivering customized volume & quality products to customers across the world, taking utmost care of their needs.

    Virtual Booth

    Contact Supplier

    With Virupaksha, you get a quality product with on-time delivery.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2025-11-24

    Virtual Booth

    Contact Supplier

    Munit offers scalable GMP micronization and particle size engineering to enhance drug solubility, bioavailability, and performance.

    Virtual Booth

    Contact Supplier

    ChemExpress delivers end-to-end CRO & CDMO solutions for small molecules, biologics & new modalities with ICH-grade quality.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2025-11-03

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    FINISHED DOSAGE FORMULATIONS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    XGen Pharmaceuticals DJB, Inc. is closely monitoring the status of the COVID-19 outbreak and its impact locally and globally. We are committed to keeping our employees and business partners safe. We are implementing our Crisis Management Plan, and we have a Business Continuity Plan to sustain operations should a quarantine or lockdown situation be put into effect. As part of our Crisis Management Plan, we are doing the followi...
    XGen Pharmaceuticals DJB, Inc. is closely monitoring the status of the COVID-19 outbreak and its impact locally and globally. We are committed to keeping our employees and business partners safe. We are implementing our Crisis Management Plan, and we have a Business Continuity Plan to sustain operations should a quarantine or lockdown situation be put into effect. As part of our Crisis Management Plan, we are doing the following: Adhering to health and safety standards, Postponing non-essential travel etc

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    XGen PharmaceuticalsUnited_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    300 Daniel Zenker Drive Horseheads, NY 14845
    Telephone
    Telephone
    +1 866.390-4411
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    http://xgenpharmadjb.com/
    Linkedin
    Linkedin
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    Default Event

    DDL Conference

    Not Confirmed

    envelop Contact Supplier

    DDL Conference

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    XGen Pharm`s Generics Nelarabine Receives Approval in US
    XGen Pharm`s Generics Nelarabine Receives Approval in US

    05 Sep 2024

    // FDA

    https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=216510

    FDA
    05 Sep 2024
    Share Share
    Xgen Pharms' Generic Pentamidine Isethionate Receives Approval in the U.S.
    Xgen Pharms' Generic Pentamidine Isethionate Receives Approval in the U.S.

    17 Mar 2022

    // FDA

    https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=206982

    FDA
    17 Mar 2022
    Share Share
    Enforcement Report - Week of August 16, 2017
    Enforcement Report - Week of August 16, 2017

    16 Aug 2017

    // FDA

    https://www.pharmacompass.com/pdf/news/enforcement-report-week-of-august-16-2017-1502850779.pdf

    FDA
    16 Aug 2017
    Share Share
    Enforcement Report - Week of April 12, 2017
    Enforcement Report - Week of April 12, 2017

    12 Apr 2017

    // FDA

    https://www.pharmacompass.com/pdf/news/enforcement-report-week-of-april-12-2017-1491972590.pdf

    FDA
    12 Apr 2017
    Share Share
    Exela Issues Voluntary Recall of Ibuprofen Lysine Injection
    Exela Issues Voluntary Recall of Ibuprofen Lysine Injection

    08 Feb 2017

    // FDA

    http://www.fda.gov/Safety/Recalls/ucm540769.htm

    FDA
    08 Feb 2017
    Share Share

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search